Skip to content
S8572Senate2021-2022 SessionSame asA2272

Cover Genetic Disease Testing

Official title

“Authorizes reimbursement for testing for familial dysautonomia, Canavan's disease and Tay-Sachs”

Sponsor Anna KaplanSD-7Affects Finance
Status
In Senate Committee
Insurance
Impact
6/10
Moderate
Passage
0%

Bill progress

Step 2 of 7

In committee · Insurance

What's happening

This bill requires insurance policies in New York to cover testing for familial dysautonomia, Canavan's disease, and Tay-Sachs.

Why it matters

  1. Expands access to critical genetic testing. by mandating insurance coverage for tests that can identify carriers or patients with familial dysautonomia, Canavan's disease, and Tay-Sachs—rare, often severe inherited disorders, particularly prevalent in certain populations.

  2. Removes cost barriers for at-risk families. by including these tests in all new insurance policies and at the renewal of existing ones, making it easier for people to get tested without worrying about out-of-pocket expenses.

  3. Emphasizes patient confidentiality. by requiring only laboratory acknowledgment as proof of testing, rather than disclosing personal medical details to insurers, helping to protect sensitive genetic information.

  4. Aligns with existing insurance structures. by allowing deductibles and co-insurance similar to other covered benefits, which could help control premium costs while still making testing broadly available.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • People seeking testing for familial dysautonomia, Canavan’s disease or Tay-Sachs

    The bill would require covered health policies to pay for testing, though annual deductibles and coinsurance could apply.

  • Health insurers and health service corporations

    The bill would require testing coverage in qualifying new policies at inception and existing policies at an anniversary date, subject to evidence of insurability.

  • Laboratories performing these tests

    Their acknowledgment that testing was performed would be sufficient evidence for coverage purposes to protect patients’ confidentiality.

  • State insurance superintendent

    The bill would allow deductibles and coinsurance deemed appropriate by the superintendent and consistent with other benefits under the policy.

Headline styles

Cover Genetic Disease Testing

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Anna Kaplan

Senator · Senate District 7

Chair, Commerce, Economic Development And Small Business

No co-sponsors yet.

History

  1. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A2272Assembly

Cover Genetic Disease Testing

In Assembly Committee · Insurance · Sponsor Jeffrey Dinowitz

Impact 6 · Moderate0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

8572

IN SENATE

March 15, 2022

Introduced by Sen. KAPLAN -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance

AN ACT to amend the insurance law, in relation to reimbursement for testing for familial dysautonomia, Canavan's disease and Tay-Sachs

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subsection (i) of section 3216 of the insurance law is amended by adding a new paragraph 36 to read as follows:

(36) (A) Every policy which provides coverage for hospital, surgical or medical care or provides reimbursement for laboratory tests or reimbursement for diagnostic X-ray services shall provide coverage for testing for familial dysautonomia, Canavan's disease and Tay-Sachs.

(B) Such coverage shall be included at the inception of all new policies and, with respect to all other policies, at any anniversary date of the policy subject to evidence of insurability.

(C) For purposes of this paragraph, in order to maintain the confidentiality of persons tested, receipt of an acknowledgment from the laboratory performing the test for familial dysautonomia, Canavan's disease and Tay-Sachs shall be deemed sufficient evidence of the performance of such testing.

(D) Such coverage may be subject to annual deductibles and co-insurance as may be deemed appropriate by the superintendent and as are consistent with those established for other benefits within a given policy.

§ 2. Subsection (l) of section 3221 of the insurance law is amended by adding a new paragraph 21 to read as follows:

(21) (A) A group policy which provides coverage for hospital, surgical or medical care or provides reimbursement for laboratory tests or reimbursement for diagnostic X-ray services shall provide coverage for testing for familial dysautonomia, Canavan's disease and Tay-Sachs.

(B) Such coverage shall be included at the inception of all new policies and, with respect to all other policies, at any anniversary date of the policy subject to evidence of insurability.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD05333-01-1

(C) For purposes of this paragraph, in order to maintain the confidentiality of persons tested, receipt of an acknowledgment from the laboratory performing the test for familial dysautonomia, Canavan's disease and Tay-Sachs shall be deemed sufficient evidence of the performance of such testing.

(D) Such coverage may be subject to annual deductibles and co-insurance as may be deemed appropriate by the superintendent and as are consistent with those established for other benefits within a given policy.

§ 3. Section 4303 of the insurance law is amended by adding a new subsection (ss) to read as follows:

(ss) (1) A medical expense indemnity corporation, a hospital service corporation or a health service corporation which provides coverage for hospital, surgical or medical care or provides reimbursement for laboratory tests or reimbursement for diagnostic X-ray services shall provide coverage for testing for familial dysautonomia, Canavan's disease and Tay-Sachs.

(2) Such coverage shall be included at the inception of all new policies and, with respect to all other policies, at any anniversary date of the policy subject to evidence of insurability.

(3) For purposes of this subsection, in order to maintain the confidentiality of persons tested, receipt of an acknowledgment from the laboratory performing the test for familial dysautonomia, Canavan's disease and Tay-Sachs shall be deemed sufficient evidence of the performance of such testing.

(4) Such coverage may be subject to annual deductibles and co-insurance as may be deemed appropriate by the superintendent and as are consistent with those established for other benefits within a given policy.

§ 4. This act shall take effect immediately.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the insurance law, in relation to reimbursement for testing for familial dysautonomia, Canavan's disease and Tay-Sachs

Purpose or general idea of bill

To authorize reimbursement for testing for Familial Dysautonomia, Canavan's disease and Tay-Sachs

Summary of provisions

Amends subsection (1) of Section 3216, subsection (1) of Section 3221 and Section 4303 of the Insurance Law, to authorize reimbursement for Familial Dysautonomia, Canavan's disease and Tay-Sachs testing.

The bill also states that in order to maintain the confidentiality of persons tested, receipt of acknowledgment from the testing facility shall be deemed sufficient evidence of testing.

Justification

Familial Dysautonomia, Canavan's disease and Tay-Sachs are genetic diseases which cause degeneration of the nervous system, and result in death. No treatment is currently available for any of these diseases, however, an infant can only be afflicted with the disease if both the mother and father are carriers. There is currently a testing system in place which screens individuals before marriage to determine if they are carriers. This legislation would ensure that for medical screening for theseindividuals are able to receive reimbursement diseases through their insurance carrier.

Prior legislative history

2019-20- A.2846 -Referred to Insurance

2017-18- A.2667-Referred to Insurance

2015-16- A.299 -Referred to Insurance

2013-14- A.4372-A- Referred to Insurance/S.209-A - Referred to Insur- ance

2011-12- A.264-Referred to Insurance/S.2880 -Referred to Insurance

2009-10- A.1134-Referred to Insurance

2007-08- A4447-Referred to Insurance

2005-06- A2424-A,Referred to Insurance

2003-04- A9263 -Referred to Insurance

Fiscal implications

None.

Effective date

This act shall take effect immediately.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.